Table 4 Joint effect of HPV16 serology and the combined risk genotypes of TNF-α SNPs on risk of OSCC
Risk groups1 | HPV16 status | Patients | Controls | Adjusted OR (95% CI)2 | ||||
|---|---|---|---|---|---|---|---|---|
(n = 325) | (n = 335) | |||||||
No. | % | No. | % | OSCC | SCCOP | Oral cavity | ||
Low-risk group | − | 61 | 18.8 | 81 | 24.2 | 1.0 | 1.0 | 1.0 |
Medium-risk group | − | 53 | 16.3 | 129 | 38.5 | 1.0 (0.3 − 1.0) | 1.0 (0.3 − 1.1) | 0.5 (0.3 − 1.0) |
High-risk group | − | 111 | 34.2 | 83 | 24.8 | 1.8 (1.1 − 2.8) | 1.8 (1.0 − 3.3) | 1.6 (0.9 − 2.8) |
Low-risk group | + | 27 | 8.3 | 13 | 3.9 | 1.5 (1.0 − 2.9) | 2.9 (1.4 − 6.2) | 0.7 (0.2 − 2.4) |
Medium-risk group | + | 23 | 7.1 | 21 | 6.3 | 2.7 (1.3 − 5.8) | 4.9 (2.2 − 11.2) | 0.2 (0.0 − 1.0) |
High-risk group | + | 50 | 15.4 | 8 | 2.4 | 8.5 (3.7 − 19.4) | 15.8 (6.5 − 38.0) | 2.3 (0.7 − 6.9) |